TIDMDXRX
Diaceutics PLC
08 September 2021
8 September 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Two new experts join the Diaceutics Advisory Panel
-- Two further Key Opinion Leaders provide their support for the
Company's DXRX platform, the world's first diagnostic
commercialisation platform for Precision Medicine
-- Diaceutics' advisory panel of global experts has more than
120 years of collective experience in Precision Medicine
testing
-- Panel is working with key stakeholders to unlock the power of
Precision Medicine and to help patients get timely access to the
treatment they deserve
-- Specialists are part of a growing global network built by
Diaceutics to transform the testing ecosystem
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation
company, announces the addition of two new Key Opinion Leaders to
its Advisory Panel of experts to support and inform the development
of its DXRX platform - the world's first diagnostic
commercialisation platform for Precision Medicine. The new
additions to the panel are Dr. Avi Kulkarni, Senior Vice President,
Global Head of Life Sciences Research & Development at
Cognizant, and Agathe Blanchon-Ehrsam, VP Long-Range Innovation and
Portfolio Development at Danone.
Dr. Avi Kulkarni has over 20 years' experience in Personalised
Medicine and brings a leadership view that integrates four pillars:
strategy, operational performance, entrepreneurship and scientific
experience and scholarship. Dr Kulkarni previously held management
consultancy roles at IQVIA and Booz & Co, before spending a
decade in the biotechnology industry around Stanford University
helping to build three biotechnology start-ups: CareDx/XDx (CDNA),
Lumen Therapeutics, and Aviir.
His focus is on capabilities-led transformation of life sciences
companies, and he has extensive experience in drug and diagnostics
product development, mergers and acquisitions, and
commercialisation processes. He has helped some of the world's
leading biotechnology companies develop cell and gene therapies,
build precision medicine capabilities, and diversify into new
businesses and markets. Dr Kulkarni will advise the Company on its
strategy through execution, including the enablement of its DXRX
platform, providing advice related to positioning, portfolio
prioritisation, product planning and business development, as well
as facilitating additional pharma industry introductions.
Agathe Blanchon-Ehrsam, will join the panel as a Strategy
Advisor for the DXRX platform. She brings over 20 years of
strategic consulting experience. Agathe has helped to build brands
and grow organisations with strategic and hands-on experience
across a variety of business situations - from vision setting,
strategy definition and leadership team facilitation, to complex
team management, marketing campaign design and KPI
optimisation.
Previously, Blanchon-Ehrsam was a founding board member of Hot
Bread Kitchen, a nonprofit organisation which developed incubation
programs for start-up food entrepreneurs. Long-term engagements for
Casa Cuervo Tequilas, Nestle, and Siemens have further developed
her deep international understanding of industry dynamics and
consumer behavior.
Dr. Avi Kulkarni, Senior Vice President, Global Head of Life
Sciences Research & Development at Cognizant said: "For decades
I have built strategies and helped enable Rx and Dx companies in
their biomarker-based transformations. As the world's first
diagnostic network for precision medicine, the DXRX platform is
already making a significant difference in how data is used and
will positively impact how patients are treated. I'm looking
forward to helping Diaceutics further develop the DXRX platform and
continue the progress made to date. "
Agathe Blanchon-Ehrsam, VP Long-Range Innovation and Portfolio
Development at Danone said: "Accelerating cancer research and
improving patient outcomes is one of the big challenges of our
generation. Solving it will require the entire healthcare ecosystem
to work together. DXRX is already changing how data is used, how
partners collaborate and how patients are treated. I'm excited
about the potential for platform business strategy to further
unlock connections and enable the move from siloed solutions to
more powerful, value-creating, and personalised answers."
Peter Keeling, CEO and Founder of Diaceutics PLC, commented
:
"We are delighted to welcome two further experts to our network.
As part of our dynamic group of advisors, Avi and Agathe will help
to guide our DXRX platform's service offering and enhance the value
we deliver to pharma companies, laboratories and diagnostic
companies. In turn, this will help to overcome the obstacles
currently present in the field of Precision Medicine and, more
importantly, greatly benefit patients by getting them access to the
right treatment at the right time."
Currently, the panel consists of Keith Kerr from Aberdeen
University School of Medicine in Scotland (Professor, Consultant
Pathologist), US-based Kenneth J. Bloom of Invicro and Ambry
Genetics (CMO, MD, FCAP), Markus Eckstein from University Hospital
Erlangen in Germany (MD) and Dr Anthony Magliocco of Protean
BioDiagnostics Inc. (Founder and CEO, Consultant Pathologist) in
the USA.
To date, the panel has undertaken extensive research into the
inefficiencies in precision medicine testing which are preventing
patients from getting the treatment they need, when they need it.
For example, the Diaceutics study discussing the impact of COVID-19
on cancer diagnosis, which was accepted as an abstract at the
prestigious 2021 American Society of Clinical Oncology (ASCO)
Annual Meeting, demonstrates from the data that there was a
significant decline in patients presenting to their primary care
physicians with suspicion of cancer for diagnostic investigation
linked to COVID-19 prevention strategies. As a result, it is
predicted that these patients may subsequently present with a more
advanced cancer. Keith Kerr, Professor of Pulmonary Pathology,
Aberdeen Royal Infirmary and Advisor at Diaceutics was an author on
this abstract.
Enquiries:
Diaceutics PLC
Philip White, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker Tel: +44 (0)20 7710
) 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny
Matthew Young
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of Precision Medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for Precision Medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFSDASIDIIL
(END) Dow Jones Newswires
September 08, 2021 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
